Skip to content

Author

C. Valenza

We have 3 of 80 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

Adjuvant treatments for stage I breast cancers of one centimeter or less.

PURPOSE OF REVIEW The increasing detection of subcentimetric breast cancers (BC) through widespread implementation of mammographic screening has raised important questions regarding the optimal management of patients with stage I tumors measuring ≤1 cm in the adjuvant setting. Although these tumors exhibit an overall e...

Letizia Matera, C. Valenza, Giuseppe Curigliano · 0 citations
Review Oct 2026

Gedatolisib for the treatment of hormone receptor-positive/HER2-negative advanced breast cancer: a European perspective.

Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer (BC) represents the most common disease subtype. Although the introduction of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) has substantially improved patient outcomes, treatment...

Letizia Matera, J. Etessami, C. Valenza et al. · 0 citations
Review Open access Jul 2026

Circulating tumor DNA in early breast cancer: Evidence, challenges, next steps

Evidence supporting ctDNA for early response monitoring during neoadjuvant therapy, postoperative minimal residual disease detection, and longitudinal molecular surveillance is summarized and ctDNA‐guided therapeutic interception strategies and emerging multimodal cell‐free DNA approaches are discussed.

S. Di Cosimo, V. Appierto, C. Reduzzi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.